



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENI

Group Art Unit: 1614

Examiner: Delacroix Muin

In re application of HUGHES ET AL)
Serial No. 10/016,850)
Filed: December 14, 2001)
For: PHARMACEUTICAL CONJUGATES WITH ENHANCED PHARMACOKINETIC)
CHARACTERISTICS)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on or before

A. Phys 30, 2003

Title_

Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed pursuant to 37 CFR 1.97(c) and is accompanied by a certification as specified in 37 CFR 1.97(e).

BEST AVAILABLE COPY

CERTIFICATION UNDER 37 CFR 1.97(e)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication (the International Search Report) from a foreign patent office (The European Patent Office) acting as the International Search Authority in a counterpart foreign (PCT) patent application no more than three months prior to the filing of this Supplemental Information Disclosure Statement (a copy of the International Search Report is enclosed).

Respectfully submitted,

rank / Wxa

Attorney for Applicant

Reg. No. 25,612

4 Venture, Suite 300

Irvine, CA 92618 (949) 450-1750

Facsimile (949) 450-1764

FJUxa/ac

						_					1 011		
Form \$70-14	149								DOCKET NO: D-3004 APPLN. NO. 10/016			0/016,	850
INFORMATION DISCLOSURE CITATION									APPLICANT: Hughes tal.				
5 2003	(Use several sheets if necessary)								FILING DATE: 12/14/01 GROUP ART: 1614				
MART							U.	S. PATEN	T DOCUMENTS				
TRADE EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	RULS	ING DATE
INDIAL												 	. <u> </u>
											R	50	
											MA TECH CENT	-CE	1/1/2
		ļ	ļ						·		MA	<u> </u>	151
											FCH CEL	6	?0 ₀₃
		1				<u> </u>	İ		<u> </u>		" CENT	R 160	0.
			-									1.700	1/29 ₀₀ -
								<u> </u>					
			 	t^-									
						F	ORE	IGN PAT	ENT DOCUMENT	S			
EXANINER INITIAL	DOCUMENT NUMBER DATE							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					1	ı						YES	NO_
	wo	00/	7	8	3	0	2	12/28/00	International			<u> </u>	
	1	0	8	8	5	5	8	04/04/01	Europe			<u> </u>	
					<u> </u>							ļ	
	l	<u> </u>	<u>. </u>	1	L	<u>.I</u>	<u>. </u>	OTHER D	OCUMENTS		l		ı
							tylaı	mide Dipe	ptide as Effective	e Immunoadju	ıvant in Rat	obits ar	ıd
	Mice," Vaccine, Vol. 19 (2001) pp. 4603-4609. Habus et al., "Synthesis, Hybridization Properties, Nuclease Stability, and Cellular Uptake the Oligonucleotide-Amino-β-cyclodextrins and Adamantane Conjugates", Bioconjugate												
									xtrins and Adama , No. 4, pp. 327		gates", <i>Biod</i>	conjuga	ite
					-			·					
	-												
			*										_
EVARA	LED.	L							DATE OCNOR	TOED:			
EXAMINER									DATE CONSIDI	EKED:	,		
									ł.				
_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,													